Atossa Therapeutics to issue stapled CVR tied to rare pediatric disease Priority Review Voucher

Atossa Therapeutics announced a plan to issue a stapled contingent value right (CVR) to shareholders tied to a potential rare pediatric disease Priority Review Voucher.